BTK and B-cell chronic lymphocytic leukemia: The irreversible oral BTK inhibitor, ibrutinib, is the first agent in this class to be approved for medicinal use by the FDA for the treatment of refractory MCL (2013) and, as the front-line therapy, in patients with newly diagnosed CLL (2014) and WM (2015) [92].